| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S1706-Breast, Inflammatory, RT +/- Olaparib | 01-JUL-24 | N | ALLIANCE | 18 | |
| CCTG | 6 | |||||
| ECOG-ACRIN | 11 | |||||
| NRG | 48 | |||||
| SWOG | 77 | |||||
| sum | 160 | |||||
| S2007-Breast, Brain Mets, Sacituzumab Govitecan | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 3 | |||||
| SWOG | 15 | |||||
| sum | 25 | |||||
| S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 9 | |||
| ECOG-ACRIN | 15 | |||||
| NRG | 7 | |||||
| SWOG | 52 | |||||
| sum | 83 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 76 | |||
| ECOG-ACRIN | 60 | |||||
| NRG | 45 | |||||
| SWOG | 197 | |||||
| sum | 378 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 16 | ||
| ECOG-ACRIN | 28 | |||||
| NRG | 19 | |||||
| SWOG | 306 | |||||
| sum | 369 | |||||
| S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | Y | ALLIANCE | 19 | |||
| ECOG-ACRIN | 31 | |||||
| NRG | 14 | |||||
| SWOG | 256 | |||||
| sum | 320 | |||||
| S2108CD-Genomic Tumor Board vs Usual Practice | Y | ALLIANCE | 81 | |||
| ECOG-ACRIN | 62 | |||||
| SWOG | 1132 | |||||
| sum | 1275 | |||||
| ERLYTX | EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | Y | ECOG-ACRIN | 3 | ||
| SWOG | 2 | |||||
| sum | 5 | |||||
| S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 10 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 7 | |||||
| SWOG | 42 | |||||
| sum | 64 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 12 | ||
| ECOG-ACRIN | 2 | |||||
| NRG | 3 | |||||
| SWOG | 23 | |||||
| sum | 40 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 7 | |||||
| SWOG | 36 | |||||
| sum | 59 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 6 | |||||
| NRG | 8 | |||||
| SWOG | 37 | |||||
| sum | 55 | |||||
| S2107-Colorectal, BRAF mut, Enc + CET +/-Nivo | 30-SEP-24 | N | ALLIANCE | 8 | ||
| ECOG-ACRIN | 14 | |||||
| NRG | 10 | |||||
| SWOG | 56 | |||||
| sum | 88 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 4 | |||
| SWOG | 3 | |||||
| sum | 7 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 110 | ||
| ECOG-ACRIN | 97 | |||||
| NRG | 107 | |||||
| SWOG | 550 | |||||
| sum | 864 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 6 | |||
| ECOG-ACRIN | 13 | |||||
| NRG | 12 | |||||
| SWOG | 78 | |||||
| sum | 109 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 2 | |||||
| SWOG | 46 | |||||
| sum | 61 | |||||
| S2200-pRCC, Adv, Cabo ± Atezo | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 3 | |||||
| SWOG | 19 | |||||
| sum | 27 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 3 | |||
| sum | 3 | |||||
| LEUK | MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ECOG-ACRIN | 1 | ||
| SWOG | 3 | |||||
| sum | 4 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 38 | |||
| ECOG-ACRIN | 40 | |||||
| SWOG | 42 | |||||
| sum | 120 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 2 | |||||
| SWOG | 14 | |||||
| sum | 18 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 27 | |||
| CCTG | 11 | |||||
| ECOG-ACRIN | 14 | |||||
| NRG | 4 | |||||
| SWOG | 64 | |||||
| sum | 120 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 856 | ||
| ECOG-ACRIN | 361 | |||||
| NRG | 478 | |||||
| SWOG | 1837 | |||||
| sum | 3532 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 22 | |||
| CCTG | 32 | |||||
| ECOG-ACRIN | 10 | |||||
| NRG | 71 | |||||
| SWOG | 112 | |||||
| sum | 247 | |||||
| S1900E-KRAS G12C: Sotorasib (AMG 510) | Y | ALLIANCE | 21 | |||
| ECOG-ACRIN | 19 | |||||
| NRG | 12 | |||||
| SWOG | 65 | |||||
| sum | 117 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| NRG | 3 | |||||
| SWOG | 10 | |||||
| sum | 16 | |||||
| S1900J-MET Amplification: Amivantamab-SC | Y | ALLIANCE | 1 | |||
| sum | 1 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 1 | |||||
| sum | 2 | |||||
| S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | 30-AUG-24 | N | ALLIANCE | 42 | ||
| ECOG-ACRIN | 31 | |||||
| NRG | 91 | |||||
| SWOG | 253 | |||||
| sum | 417 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 5 | |||
| NRG | 1 | |||||
| SWOG | 33 | |||||
| sum | 39 | |||||
| S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | Y | ALLIANCE | 135 | |||
| ECOG-ACRIN | 79 | |||||
| NRG | 52 | |||||
| SWOG | 488 | |||||
| sum | 754 | |||||
| LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 15-JUL-24 | N | ALLIANCE | 17 | |
| ECOG-ACRIN | 5 | |||||
| NRG | 11 | |||||
| SWOG | 45 | |||||
| sum | 78 | |||||
| S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | Y | ALLIANCE | 36 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 7 | |||||
| SWOG | 62 | |||||
| sum | 122 | |||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 13 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 4 | |||||
| SWOG | 64 | |||||
| sum | 86 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | Y | ALLIANCE | 5 | |||
| NRG | 4 | |||||
| SWOG | 18 | |||||
| sum | 27 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 1 | |||||
| SWOG | 4 | |||||
| sum | 6 | |||||
| MELAN | S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 18-JUN-24 | N | ALLIANCE | 1 | |
| ECOG-ACRIN | 6 | |||||
| NRG | 1 | |||||
| SWOG | 29 | |||||
| sum | 37 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 214 | ||
| CCTG | 18 | |||||
| ECOG-ACRIN | 182 | |||||
| NRG | 109 | |||||
| SWOG | 740 | |||||
| sum | 1263 | |||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ECOG-ACRIN | 6 | |||
| NRG | 1 | |||||
| SWOG | 2 | |||||
| sum | 9 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 3 | |||||
| SWOG | 40 | |||||
| sum | 49 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 1 | |||
| SWOG | 4 | |||||
| sum | 5 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 8 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 5 | |||||
| SWOG | 34 | |||||
| sum | 54 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 43 | ||
| SWOG | 220 | |||||
| S1501 | Y | ALLIANCE | 23 | |||
| NRG | 24 | |||||
| sum | 310 | |||||
| PREV | S1904-Breast, Decision making for chemoprevention | 14-JUN-24 | N | ALLIANCE | 106 | |
| ECOG-ACRIN | 43 | |||||
| NRG | 85 | |||||
| SWOG | 178 | |||||
| sum | 412 | |||||
| SXQOL | S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | Y | ALLIANCE | 34 | ||
| ECOG-ACRIN | 28 | |||||
| NRG | 75 | |||||
| SWOG | 354 | |||||
| sum | 491 | |||||
| S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 351 | |||
| ECOG-ACRIN | 109 | |||||
| NRG | 255 | |||||
| SWOG | 1369 | |||||
| sum | 2084 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 46 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 63 | |||||
| SWOG | 138 | |||||
| sum | 252 | |||||